Patient's own immune cells effective as living medicine for melanoma



Patient’s own immune cells effective as living medicine for melanoma

A patient’s own immune cells, multiplied into an army of billions of immune cells in a lab, can be used as a living medicine against metastatic melanoma, an aggressive form of skin cancer, as the TIL trial has shown. The TIL trial is the world’s first comparative phase 3 trial looking into the effect of T cell therapy in melanoma, and solid tumors in general.

Materials provided by Netherlands Cancer Institute. Note: Content may be edited for style and length.




Source link aaaaa

Related posts

1st June 2023

Open-analysis platform for pediatric brain tumors provides robust data resource for childhood cancer research

Read more
31st May 2023

Plants remove cancer causing toxins from air

Read more
31st May 2023

How the flu virus hacks our cells

Read more